Cargando…

Precision medicine approaches to lung adenocarcinoma with concomitant MET and HER2 amplification

BACKGROUND: Patient-derived xenograft (PDX) models are important tools in precision medicine and for the development of targeted therapies to treat cancer patients. This study aimed to evaluate our precision medicine strategy that integrates genomic profiling and preclinical drug-screening platforms...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oh, Doo-Yi, Jung, Kyungsoo, Song, Ji-Young, Kim, Seokhwi, Shin, Sang, Kwon, Yong-Jun, Oh, Ensel, Park, Woong-Yang, Song, Sang Yong, Choi, Yoon-La
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557466/ https://www.ncbi.nlm.nih.gov/pubmed/28806950 http://dx.doi.org/10.1186/s12885-017-3525-9

Ejemplares similares

HER2 as a novel therapeutic target for cervical cancer
por: Oh, Doo-Yi, et al.
Publicado: (2015)

Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy
por: Gu, Fei-fei, et al.
Publicado: (2016)

LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients
por: Kim, Yu Jin, et al.
Publicado: (2016)

Prognostic Significance of HER2 Gene Amplification According to Stage of Breast Cancer
por: Kim, Yong-Seok, et al.
Publicado: (2008)

Engrailed 1 overexpression as a potential prognostic marker in quintuple-negative breast cancer
por: Kim, Yu Jin, et al.
Publicado: (2018)

IRS2 Amplification as a Predictive Biomarker in Response to Ceritinib in Small Cell Lung Cancer
por: Lee, Mi-Sook, et al.
Publicado: (2020)

Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification
por: Tanizaki, J, et al.
Publicado: (2011)

Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer
por: Kwak, Yoonjin, et al.
Publicado: (2017)

Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2017)

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma
por: Zhang, Jing, et al.
Publicado: (2016)

Significance of HER2 protein expression and HER2 gene amplification in colorectal adenocarcinomas
por: Wang, Xin-Yu, et al.
Publicado: (2019)

Phenylethanolamine N-methyltransferase downregulation is associated with malignant pheochromocytoma/paraganglioma
por: Lee, Seung Eun, et al.
Publicado: (2016)

Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma
por: KATO, HIROAKI, et al.
Publicado: (2013)

HER2 Oncogene Amplification and Immunohistochemical Profiling in Gastric Adenocarcinoma
por: Raj, Nisha, et al.
Publicado: (2018)

Combination treatment with trastuzumab and crizotinib in metastatic gastric cancer harboring Her-2 amplification and c-MET amplification: A case report
por: Liu, Mingsheng
Publicado: (2021)

GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma
por: Kwon, Ok-Seon, et al.
Publicado: (2015)

Identification of Novel Reference Genes Using Multiplatform Expression Data and Their Validation for Quantitative Gene Expression Analysis
por: Kwon, Mi Jeong, et al.
Publicado: (2009)

Correction: Identification of Novel Reference Genes Using Multiplatform Expression Data and Their Validation for Quantitative Gene Expression Analysis
por: Kwon, Mi Jeong, et al.
Publicado: (2009)

MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma
por: Catenacci, Daniel V. T., et al.
Publicado: (2016)

A novel co-existing ZCCHC8-ROS1 and de-novo MET amplification dual driver in advanced lung adenocarcinoma with a good response to crizotinib
por: Zhu, You-cai, et al.
Publicado: (2018)

Model-informed precision dosing in vancomycin treatment
por: Yoon, Sukyong, et al.
Publicado: (2023)

Continuous quantification of HER2 expression by microfluidic precision immunofluorescence estimates HER2 gene amplification in breast cancer
por: Dupouy, Diego G., et al.
Publicado: (2016)

Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue
por: Catenacci, Daniel V. T., et al.
Publicado: (2014)

MET Expression Level in Lung Adenocarcinoma Loosely Correlates with MET Copy Number Gain/Amplification and Is a Poor Predictor of Patient Outcome
por: Yin, Wei, et al.
Publicado: (2022)

Genetic Information and Precision Medicine in Hearing Loss
por: Oh, Doo-Yi, et al.
Publicado: (2020)

Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling
por: Park, Silvia, et al.
Publicado: (2014)

Comparison of Accuracy of Whole-Exome Sequencing with Formalin-Fixed Paraffin-Embedded and Fresh Frozen Tissue Samples
por: Oh, Ensel, et al.
Publicado: (2015)

Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
por: Hassan, Md. Sazzad, et al.
Publicado: (2019)

HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma
por: HUANG, JUN-XING, et al.
Publicado: (2013)

TOPOIIα and HER-2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinoma
por: Rossi, Elisa, et al.
Publicado: (2010)

An analysis of HER2 amplification in cervical adenocarcinoma: correlation with clinical outcomes and the International Endocervical Adenocarcinoma Criteria and Classification
por: Shi, Haiyan, et al.
Publicado: (2020)

Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification
por: Sang, Yun Beom, et al.
Publicado: (2023)

Successful crizotinib monotherapy in EGFR-mutant lung adenocarcinoma with acquired MET amplification after erlotinib therapy
por: Yoshimura, Katsuhiro, et al.
Publicado: (2017)

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification
por: Wang, Jieyi, et al.
Publicado: (2016)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

Multiplex Droplet Digital PCR Assay for Detection of MET and HER2 Genes Amplification in Non-Small Cell Lung Cancer
por: Oscorbin, Igor P., et al.
Publicado: (2022)

MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
por: Yoshimura, Katsuhiro, et al.
Publicado: (2021)

Molecular changes in solitary fibrous tumor progression
por: Park, Hyung Kyu, et al.
Publicado: (2019)

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
por: Peng, Lun-Xi, et al.
Publicado: (2021)

Correlation of MET-Receptor Overexpression with MET Gene Amplification and Patient Outcome in Malignant Mesothelioma
por: Santoni-Rugiu, Eric, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fdf1u9i2pgsqugghnibedvrthm